Charles River Laboratories CRL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $995.83M+0.2% | $994.23M-1.1% | $1B-2.6% | $1.03B+4.9% | $984.17M-1.8% | ||
| $159.42M-18.7% | $196.14M+10.4% | $177.59M-7.3% | $191.55M+7.7% | $177.8M-9.2% | ||
| $119.9M— | —— | $133.8M+33.6% | $100.13M+34.1% | $74.67M— | ||
| 12%— | —— | 13.3%+3.6pp | 9.7%+2.1pp | 7.6%— | ||
| $26.74M+12.5% | $23.78M-6.4% | $25.4M-15.2% | $29.97M+7.5% | $27.88M-1.2% | ||
| -$124.13M— | —— | -$22.62M-14,787% | $154K+101% | -$12.21M+46.2% | ||
| -$15.14M— | —— | $31.64M+69.0% | $18.73M+85.4% | $10.1M— | ||
| -$14.84M+94.6% | -$276.56M-608% | $54.42M+4.0% | $52.33M+105% | $25.47M— | ||
| -1.5%+26.3pp | -27.8%-33.2pp | 5.4%+0.3pp | 5.1%+2.5pp | 2.6%— | ||
| -$0.30+94.6% | -$5.56-605% | $1.10+3.8% | $1.06+112% | $0.50— | ||
| $187.05M+142% | $77.18M-64.8% | $218.96M-0.3% | $219.64M+12.6% | $195.03M+27.0% | ||
| 18.8%+11.0pp | 7.8%-14.0pp | 21.8%+0.5pp | 21.3%+1.5pp | 19.8%+4.5pp | ||
| $119.9M+10,992% | -$1.1M-101% | $133.8M+33.6% | $100.13M+34.1% | $74.67M+45.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Charles River Laboratories's revenue?
- Charles River Laboratories (CRL) generated $4.0B in revenue over the trailing twelve months, up 0.1% year over year.
- Is Charles River Laboratories profitable?
- Charles River Laboratories is not currently profitable: it reported a net loss of $184.7M over the trailing twelve months, a -4.6% net margin.
- What are Charles River Laboratories's profit margins?
- Gross margin is 84.7% and operating margin is 13.0%, with a -4.6% net margin.
- What is Charles River Laboratories's earnings per share?
- Charles River Laboratories's diluted EPS over the trailing twelve months is $-3.70.
- Where does Charles River Laboratories's income statement data come from?
- Every line is extracted from Charles River Laboratories's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
